Sanyou Bio Applauds Eluminex Biosciences and Foreseen Biotechnology for Drug Innovation Breakthroughs

On July 15, Eluminex Biosciences administered the first dose of their tri-specific fusion antibody drug, EB-105, to a diabetic macular edema patient in the United States as part of their LOTUS clinical trial. This trial is an open-label, multicenter, single-dose, dose-escalation study involving intravitreal injections and is being conducted across four U.S. hospitals.

A week later, on July 22, Foreseen Biotechnology announced the global licensing of their ADC targeted drug, FS001, to Ipsen Pharma SAS of France. Ipsen has secured exclusive rights to develop, manufacture, and commercialize FS001 worldwide. The licensing agreement involves payments, milestones, and royalties totaling $1.03 billion.

Eluminex Biosciences's drug EB-105 has demonstrated promising results in preclinical studies, effectively inhibiting signal transduction pathways like VEGF-A/VEGFR-2, Ang-2/Tie-2, and IL-6/IL-6R. By targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), and inhibiting intracellular inflammation-related pathways, EB-105 could offer superior therapeutic effects for diabetic retinopathy patients compared to existing treatments.

Foreseen Biotechnology's FS001 is built on a novel tumor-associated antigen they discovered. The drug boasts excellent targeting activity and high specificity. FS001 employs an innovative, stable, cleavable linker paired with a potent topoisomerase I inhibitor, showing promising preclinical efficacy in various drug-resistant cancer models.

Sanyou Bio played a pivotal role in assisting both Eluminex Biosciences and Foreseen Biotechnology in the discovery of these innovative drugs. Dr. Guojun Lang, CEO of Sanyou Bio, expressed pride in supporting their efforts and wished for the continued success of these projects, hoping they soon achieve clinical success to benefit patients globally.

Eluminex Biosciences was established in early 2020. The company’s headquarters, research and development (R&D) center, and Good Manufacturing Practices (GMP) manufacturing facilities are located in Suzhou Industrial Park BioBAY, China, and it also has a regional office in Mountain View, California. Supported by leading venture groups such as Lilly Asia Ventures, Quan Capital, Hillhouse Ventures, and Cenova Capital, Eluminex has raised over $100 million through Series B+ financing.

Foreseen Biotechnology is an emerging biotech company that pioneered a high throughput integrated translational proteomics platform. This platform, powered by an AI-based data analytical system, accelerates the discovery of novel therapeutic and diagnostic targets. They are building a pipeline of innovative product candidates for cancer, inflammatory/autoimmune diseases, and neurological disorders. The company is incubated by Nest.Bio Ventures.

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading biotech enterprise focusing on the R&D and services of innovative biologic drugs. Sanyou has developed an integrated innovative biologic drug R&D laboratory with advanced facilities and a professional team, most of whom hold Ph.D. or master’s degrees. They have established three industry-leading innovative technology platforms and more than 50 sub-platforms. Sanyou’s business network spans Asia, the U.S., and Europe, with branches in Boston, Philadelphia, San Diego, and London. They have established business relationships with over 1000 pharmaceutical and diagnostics companies worldwide and have received national-level certification as a high-tech enterprise, along with ISO9001 quality assurance and GB/T intellectual property management system certifications.